RxDoctor Payments Data

Temitope Ajayi

Family · Hyattsville, MDNPI 1538775515

Payments from drug & device makers

$1,523in general payments, 2019–2025

Across 49 payments — averaging $31.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$463
  • Novo Nordisk$398
  • Bayer$335
  • Smith+Nephew$106
  • Zealand Pharma US, Inc.$86
  • Lilly USA, LLC$52
  • plus $82 from 3 others

What the payments were for

  • Food & beverage$1,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)12$463
Novo Nordisk20$398
Bayer7$335
Smith+Nephew1$106
Zealand Pharma US, Inc.1$86
Lilly USA, LLC3$52
Merck2$31
Pfizer2$29
AstraZeneca1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,523 in reported general payments places this provider in the 75th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$32,946
Medicare patients
133
Services billed
999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$40,116
EliquisApixaban17$20,214
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$13,211
JanumetSitagliptin Phos/Metformin Hcl13$12,249
Atorvastatin Calcium237$2,768
Rosuvastatin Calcium84$2,430
Albuterol Sulfate HfaAlbuterol Sulfate77$2,135
Levothyroxine Sodium38$1,708
Ezetimibe41$1,699
Losartan Potassium120$1,460
Amlodipine Besylate163$1,452
Metoprolol Succinate56$998
Pantoprazole Sodium44$767
Gabapentin37$734
Divalproex Sodium ErDivalproex Sodium12$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$398$40,11634 claims
PfizerEliquis$29$20,21417 claims
MerckJanumet$31$12,24913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,843 family providers in Maryland.

Other family in Hyattsville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →